398 related articles for article (PubMed ID: 25052208)
1. Vulvovaginal Candida albicans infections: pathogenesis, immunity and vaccine prospects.
Cassone A
BJOG; 2015 May; 122(6):785-794. PubMed ID: 25052208
[TBL] [Abstract][Full Text] [Related]
2. Analysis of pathogenic factors of Candida albicans and the effect of vaginal immunization on recurrent vulvovaginal candidiasis in mice.
Shao MK; Qi WJ; Hou MY; Luo DD
J Obstet Gynaecol Res; 2022 Mar; 48(3):857-865. PubMed ID: 34970814
[TBL] [Abstract][Full Text] [Related]
3. Distinct host immune responses in recurrent vulvovaginal candidiasis and vulvovaginal candidiasis.
Ge G; Yang Z; Li D; Zhang N; Chen B; Shi D
Front Immunol; 2022; 13():959740. PubMed ID: 35967437
[TBL] [Abstract][Full Text] [Related]
4. Candida vaginitis: virulence, host response and vaccine prospects.
De Bernardis F; Graziani S; Tirelli F; Antonopoulou S
Med Mycol; 2018 Apr; 56(suppl_1):26-31. PubMed ID: 29538739
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of Candida albicans secreted aspartyl proteinase in human vulvovaginal candidiasis.
Lian CH; Liu WD
Mycoses; 2007 Sep; 50(5):383-90. PubMed ID: 17714358
[TBL] [Abstract][Full Text] [Related]
6. Anticandidal immunity and vaginitis: novel opportunities for immune intervention.
Cassone A; De Bernardis F; Santoni G
Infect Immun; 2007 Oct; 75(10):4675-86. PubMed ID: 17562759
[No Abstract] [Full Text] [Related]
7. Microbicidal activity of neutrophils is inhibited by isolates from recurrent vaginal candidiasis (RVVC) caused by Candida albicans through fungal thioredoxin reductase.
Ratti BA; Godoy JS; de Souza Bonfim Mendonça P; Bidóia DL; Nakamura TU; Nakamura CV; Lopes Consolaro ME; Estivalet Svidzinski TI; de Oliveira Silva S
Cell Immunol; 2015 Jan; 293(1):22-9. PubMed ID: 25497972
[TBL] [Abstract][Full Text] [Related]
8. Patients with recurrent vulvovaginal candidiasis exhibit a decrease in both the fungicidal activity of neutrophils and the proliferation of peripheral blood mononuclear cells.
Consuegra-Asprilla JM; Rodríguez-Echeverri C; Posada DH; Gómez BL; González Á
Mycoses; 2024 Apr; 67(4):e13720. PubMed ID: 38551114
[TBL] [Abstract][Full Text] [Related]
9. NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response.
Ibrahim AS; Luo G; Gebremariam T; Lee H; Schmidt CS; Hennessey JP; French SW; Yeaman MR; Filler SG; Edwards JE
Vaccine; 2013 Nov; 31(47):5549-56. PubMed ID: 24063977
[TBL] [Abstract][Full Text] [Related]
10. A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis-A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial.
Edwards JE; Schwartz MM; Schmidt CS; Sobel JD; Nyirjesy P; Schodel F; Marchus E; Lizakowski M; DeMontigny EA; Hoeg J; Holmberg T; Cooke MT; Hoover K; Edwards L; Jacobs M; Sussman S; Augenbraun M; Drusano M; Yeaman MR; Ibrahim AS; Filler SG; Hennessey JP
Clin Infect Dis; 2018 Jun; 66(12):1928-1936. PubMed ID: 29697768
[TBL] [Abstract][Full Text] [Related]
11. Microsatellite analysis of Candida isolates from recurrent vulvovaginal candidiasis.
Amouri I; Sellami H; Abbes S; Hadrich I; Mahfoudh N; Makni H; Ayadi A
J Med Microbiol; 2012 Aug; 61(Pt 8):1091-1096. PubMed ID: 22538998
[TBL] [Abstract][Full Text] [Related]
12. The Elusive Anti-
Tso GHW; Reales-Calderon JA; Pavelka N
Front Immunol; 2018; 9():897. PubMed ID: 29755472
[TBL] [Abstract][Full Text] [Related]
13. [Local humoral immunity in vulvovaginal candidiasis].
Amouri I; Hadrich I; Abbes S; Sellami H; Ayadi A
Ann Biol Clin (Paris); 2013; 71(2):151-5. PubMed ID: 23587578
[TBL] [Abstract][Full Text] [Related]
14. Virulence is one of the mechanisms of vulvovaginal candidiasis recurrence, rather than drug resistance.
Li X; Chen S; Lyu X; Tian J
Med Mycol; 2022 Nov; 60(11):. PubMed ID: 36328948
[TBL] [Abstract][Full Text] [Related]
15. Recurrent vulvovaginal candidiasis: why does it occur?
Rodgers CA; Beardall AJ
Int J STD AIDS; 1999 Jul; 10(7):435-9; quiz 440-1. PubMed ID: 10454177
[No Abstract] [Full Text] [Related]
16. An intravaginal live Candida challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis.
Fidel PL; Barousse M; Espinosa T; Ficarra M; Sturtevant J; Martin DH; Quayle AJ; Dunlap K
Infect Immun; 2004 May; 72(5):2939-46. PubMed ID: 15102806
[TBL] [Abstract][Full Text] [Related]
17. A comparative investigation of azole susceptibility in Candida isolates from vulvovaginal candidiasis and recurrent vulvovaginal candidiasis patients in Ghana.
Adjapong G; Hale M; Garrill A
Med Mycol; 2017 Aug; 55(6):686-689. PubMed ID: 27838642
[TBL] [Abstract][Full Text] [Related]
18. β-Glucan induces reactive oxygen species production in human neutrophils to improve the killing of Candida albicans and Candida glabrata isolates from vulvovaginal candidiasis.
Bonfim-Mendonça Pde S; Ratti BA; Godoy Jda S; Negri M; Lima NC; Fiorini A; Hatanaka E; Consolaro ME; de Oliveira Silva S; Svidzinski TI
PLoS One; 2014; 9(9):e107805. PubMed ID: 25229476
[TBL] [Abstract][Full Text] [Related]
19. Different expression levels of
Bonfim-Mendonça PS; Tobaldini-Valério FK; Capoci IR; Faria DR; Sakita KM; Arita GS; Negri M; Kioshima ÉS; Svidzinski TI
Future Microbiol; 2021 Mar; 16():211-219. PubMed ID: 33595345
[No Abstract] [Full Text] [Related]
20. Novel Mechanism behind the Immunopathogenesis of Vulvovaginal Candidiasis: "Neutrophil Anergy".
Yano J; Peters BM; Noverr MC; Fidel PL
Infect Immun; 2018 Mar; 86(3):. PubMed ID: 29203543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
